Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009.
about
Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitroInfluenza and the use of oseltamivir in childrenRecent progress in structure-based anti-influenza drug designMolecular modeling of swine influenza A/H1N1, Spanish H1N1, and avian H5N1 flu N1 neuraminidases bound to Tamiflu and RelenzaInhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion proteinOseltamivir-resistant pandemic A/H1N1 virus is as virulent as its wild-type counterpart in mice and ferretsOseltamivir-resistant pandemic H1N1/2009 influenza virus possesses lower transmissibility and fitness in ferretsTriple combination antiviral drug (TCAD) composed of amantadine, oseltamivir, and ribavirin impedes the selection of drug-resistant influenza A virusDetection of peramivir and laninamivir, new anti-influenza drugs, in sewage effluent and river waters in JapanSensitive Detection and Simultaneous Discrimination of Influenza A and B Viruses in Nasopharyngeal Swabs in a Single Assay Using Next-Generation Sequencing-Based DiagnosticsAntigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humansTwo years after pandemic influenza A/2009/H1N1: what have we learned?Prevalence of antibodies against seasonal influenza A and B viruses during the 2009-2010 and 2010-2011 influenza seasons in residents of Pittsburgh, PA, USAClinical Profile of Patients Admitted with Swine-Origin Influenza A (H1N1) Virus Infection: An Experience from A Tertiary Care Hospital.Prevalence of Oseltamivir-Resistant 2009 H1N1 Influenza Virus among Patients with Pandemic 2009 H1N1 Influenza infection in NRITLD, Tehran, IranAntiviral drug profile of human influenza A & B viruses circulating in India: 2004-2011.Clinical and epidemiologic characteristics of 3 early cases of influenza A pandemic (H1N1) 2009 virus infection, People's Republic of China, 2009.The novel influenza A (H1N1) virus pandemic: An update.Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein.H1N1 influenza A infectionPost-exposure prophylaxis during pandemic outbreaksUse of oseltamivir in childrenEffectiveness and cost-effectiveness of expanded antiviral prophylaxis and adjuvanted vaccination strategies for an influenza A (H5N1) pandemicDetection of molecular markers of drug resistance in 2009 pandemic influenza A (H1N1) viruses by pyrosequencing.Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza.Rapid detection of influenza A pandemic (H1N1) 2009 virus neuraminidase resistance mutation H275Y by real-time reverse transcriptase PCR.Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hostsIn vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.Diagnostic approach for the differentiation of the pandemic influenza A(H1N1)v virus from recent human influenza viruses by real-time PCRDiagnostic testing for pandemic influenza in Singapore: a novel dual-gene quantitative real-time RT-PCR for the detection of influenza A/H1N1/2009.Characterization of oseltamivir-resistant 2009 H1N1 pandemic influenza A virusesClinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in an university hospital of MoroccoThe anti-tumor agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), induces IFN-beta-mediated antiviral activity in vitro and in vivo.Pandemic H1N1 2009 influenza virus with the H275Y oseltamivir resistance neuraminidase mutation shows a small compromise in enzyme activity and viral fitness.Multidrug-resistant 2009 pandemic influenza A(H1N1) viruses maintain fitness and transmissibility in ferrets.Deep sequencing reveals mixed infection with 2009 pandemic influenza A (H1N1) virus strains and the emergence of oseltamivir resistance.Oseltamivir-resistant pandemic (H1N1) 2009 virus, Mexico.Strategies for the use of oseltamivir and zanamivir during pandemic outbreaks.Monitoring and characterization of oseltamivir-resistant pandemic (H1N1) 2009 virus, Japan, 2009-2010.The first influenza pandemic of the new millennium.
P2860
Q21142648-B610903D-E5B2-447A-9464-A2A514DCCCE9Q26739661-AB3C5C14-FFFC-4493-B154-B02CE6710A88Q26863710-2EA6E3FC-D6CA-4817-BB3B-6CF5DE3A3C48Q28471585-98DD53D2-DDEE-4400-A439-B9AA86A7E644Q28471835-2ADED2FC-98B9-40D6-B64F-9E71CFC26443Q28474889-FE13B0C9-3F46-49EE-BF46-1190896EE005Q28474960-EEF7A296-BA1C-4C44-A14C-4E865CF62487Q28478637-A348C721-35E3-4A63-A03C-4309EEA1CCF2Q28545776-CB3F9EF7-1CB3-40B6-AFBB-21AE69328C09Q28554325-FEA56CA7-2704-4866-AA17-74D561C95030Q29619059-22A6EEEE-33FC-4292-BB0A-800F1FEB9D2CQ30224656-9B7C0354-BF26-4AD6-A67D-C37B0F401A02Q30224919-91745B29-09A8-486B-9E68-D34943B3ED4CQ30356317-ADBF2311-2047-4B98-AC41-2C386D1752F2Q30366471-3546A969-5A8A-45E5-AE91-C55E2F7C2B06Q30367631-97D11AE5-D2D8-4FEE-9E60-86AA11824444Q30381166-1283FF2A-5151-439D-B78F-61541A6F5E7AQ30382148-F98093C7-0391-45B2-BCD8-3299FDDBFC9AQ30382312-84B8E66B-D9D8-43A2-B2AC-9A71421F6E73Q30382598-11C38ED0-7E07-4BE8-B12D-93D3E0629FC6Q30383105-F24CCA67-2BDF-4B98-8EA5-7BA02BC322BAQ30383447-EC99559E-0492-4765-B226-32925A2F572AQ30383451-AD671B3E-8936-448E-ABA2-04D50EA1346CQ30383771-D131EA71-26D5-4298-B5D6-4AFB85D6D34BQ30385708-9118C11D-65FA-43C1-8226-40804BFCF68AQ30386535-07E8D84B-B19B-484B-8DB4-570A3BC9A760Q30387332-5E1C2BF6-5DFE-4DDD-AFCB-DF5F25BF0573Q30387420-390719FC-1CD1-4142-ABCD-1BBE38B981E9Q30387864-BEEAB91C-D585-438D-93E9-F7F1C3ED16C6Q30392355-6E36CE28-E03F-4D8B-86E8-171BB4D14655Q30394067-AE15DD44-F0AB-467F-AD8B-59A9E0D33DD4Q30395318-44083A24-F3BC-4B8C-B061-C8A703993264Q30396361-0987A1F9-DFCA-4D38-88D6-64D2D1A1FC46Q30397718-0FD03D7F-22C6-4F81-9E8A-3B5D9352B9E3Q30398271-50663F99-B927-4370-97C0-E0D6282B12E3Q30399274-314BE7AB-3602-4F7B-B986-C43A09441414Q30399321-37F018A7-0121-4E56-95BF-FA92A31EE560Q30400232-EE813DDC-B824-4EB1-BA91-D63D685C7ADFQ30400621-2C51D228-5414-4A49-9C22-9F1D823F51B3Q30401658-CE2B21C8-1ECC-404D-BD33-14F7F7A11C3F
P2860
Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009.
@en
Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009.
@nl
type
label
Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009.
@en
Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009.
@nl
prefLabel
Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009.
@en
Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009.
@nl
P1476
Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009
@en
P304
P577
2009-05-01T00:00:00Z